AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04643327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
Trial: NCT05930171
Drug: Postoperative conventional analgesia in form of Acetaminophen
RxNorm normalized name: acetaminophen / phenyltoloxamine citrate Oral Capsule [Dolorex brand of acetaminophen-phenyltoloxamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
Trial: NCT06106880
Drug: Wintergreen Throat Spray and Aspirin Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet
Trial: NCT06106880
Drug: Aspirin Throat Spray and Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients.
Trial: NCT05742256
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
Trial: NCT05556460
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will continue to be managed on medical therapy, per physician discretion
Trial: NCT03052569
Drug: RXDX-105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsules
Trial: NCT05183334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05160402
Drug: IGM-6268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator
Trial: NCT05160402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT06301529
Drug: Invokana Pill
RxNorm normalized name: Invokana Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg and 150 mg doses, taken every day and every-other day, respectively.
Trial: NCT05320861
Drug: [14C]SJP-0008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of \[14C\]SJP-0008
Trial: NCT05018702
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
Trial: NCT04780672
Drug: Molixan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
Trial: NCT04780672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
Trial: NCT06608459
Drug: PEX010-Assisted Therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.
Trial: NCT05205304
Drug: D'Oxyva
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
Trial: NCT04978337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to rilematovir will be administered orally.
Trial: NCT04824898
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation
Trial: NCT05230797
Drug: Zinc oxide Propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibacterial and anti-inflammatory
Trial: NCT05230797
Drug: Zinc Oxide-Eugenol Cement
RxNorm normalized name: Eugenol
DrugBank: Eugenol (DB09086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimicrobial and antiseptic
Trial: NCT06519981
Drug: HRS-9231or matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-9231 injection or matching placebo will be administered through IV injection.
Trial: NCT02942706
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin+LV5FU2
Trial: NCT05886088
Drug: LID104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT05307679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral placebo
Trial: NCT04872387
Drug: BAY2586116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal administration
Trial: NCT04872387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06521190
Drug: ACOU085 (bimokalner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transtympanic injection
Trial: NCT06521190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transtympanic injection
Trial: NCT05582278
Drug: D-TACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
Trial: NCT05582278
Drug: HAIC
RxNorm normalized name: Hepatic Arterial Infusion Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Trial: NCT00002029
Drug: Fat Emulsion 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002029
Drug: Fat Emulsion 20%
RxNorm normalized name: Fat Emulsion 20% Intravenous Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06720506
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be given intrathecal with dose 10-20ug
Trial: NCT05454020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
Trial: NCT06720805
Drug: Pentabiocel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires.
Trial: NCT06720805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires.
Trial: NCT04944784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT05672498
Drug: Traditional Chinese Medicine Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
Trial: NCT05733000
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receive IV
Trial: NCT04903912
Drug: Medical treatment according to current guidelines
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
Trial: NCT04717362
Drug: Natesto Nasal Product
RxNorm normalized name: Natesto Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
Trial: NCT04520685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
Trial: NCT05624229
Drug: Proton Pump Inhibitors
RxNorm normalized name: Proton pump inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI infusion continued to use for 5 days in experimental group
Trial: NCT05624229
Drug: No Proton Pump Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI infusion stopped in standard group after endoscopy.
Trial: NCT05246618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex-vivo infusion
Trial: NCT06453304
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracanal medication
Trial: NCT06453304
Drug: Leddermix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracanal medication
Trial: NCT06453304
Drug: Glycirrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracanal medication
Trial: NCT06217666
Drug: PCX-12
RxNorm normalized name: PCxx Neutral Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment combining radiation therapy with PCX12
Trial: NCT05647122
Drug: AZD9592
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varying doses of AZD9592
Trial: NCT05647122
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT05840159
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.
Trial: NCT05594147
Drug: Non-TKIs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
Trial: NCT05582421
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intracanal medication
Trial: NCT05132660
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill of similar size/shape
Trial: NCT05582629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
Trial: NCT04967521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally twice a day. Each cycle is 28 days.
Trial: NCT05609682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given for two weeks after surgery
Trial: NCT04710875
Drug: Na-lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT05343819
Drug: AON-D21
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Trial: NCT05343819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic glucose solution identical in appearance to AON-D21.
Trial: NCT05144854
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05626920
Drug: Disulfiram 250 mg
RxNorm normalized name: disulfiram 250 MG
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram treatment
Trial: NCT05626920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT06269900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
Trial: NCT04741646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match Ferric Citrate tablets
Trial: NCT03707418
Drug: Heparin Sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
Trial: NCT06047379
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
Trial: NCT05082233
Drug: SHR7280 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
Trial: NCT00231517
Drug: topical opiod
RxNorm normalized name: Morphinan derivatives, opiod analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06612411
Drug: Dead B. subtilis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules, 3 times a day, orally taken for one month
Trial: NCT06612775
Drug: Test drug CB03-154 5mg group
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB03-154 tablet (5mg/tablet) once daily.
Trial: NCT06612775
Drug: Test drug CB03-154 10mg group
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two CB03-154 tablets (5mg/tablet) once daily.
Trial: NCT06612775
Drug: Test drug CB03-154 20mg group
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four CB03-154 tablets (5mg/tablet) once daily.
Trial: NCT06612775
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four Placebo tablets once daily.
Trial: NCT01514942
Drug: Folic acid, vit B12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
Trial: NCT05758818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
Trial: NCT04859946
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05289375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
Trial: NCT05621668
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT04882098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo as SC injection.
Trial: NCT02988245
Drug: Geneticure Panel for HTN therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
Trial: NCT02988245
Drug: JNC-8
RxNorm normalized name: FACTOR VIIA,RECOMBINANT-JNCW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using JNC-8 guidelines to guide therapy
Trial: NCT05478720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of saline
Trial: NCT05427162
Drug: Prostacyclin Receptor Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin receptor agonist will be administered.
Trial: NCT05996627
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06247488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive oral dose of placebo.
Trial: NCT05672173
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06083883
Drug: NY-ESO-1 TCR/IL-15 NK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06083883
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06226571
Drug: Chemotherapy Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
Trial: NCT06226571
Drug: HiDAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation: Participants will receive HiDAC IV.
Trial: NCT05328297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules will be administered orally.
Trial: NCT06213649
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
Trial: NCT05411718
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06236139
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04944290
Drug: Simbrinza 0.2%/1% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product
Trial: NCT05107999
Drug: Zhizhu Kuanzhong capsules (ZZKZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FD patients were treated with ZZKZ and omeprazole for 4 weeks.
Trial: NCT05262218
Drug: PBF-680 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBF-680 10mg administered orally once a day
Trial: NCT05262218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally once a day
Trial: NCT05028153
Drug: Azithromycin Oral Liquid Product
RxNorm normalized name: azithromycin Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg for 3 consecutive days